

12-15-05

PTO/SB/21 (6-99)

Please type a plus sign (+) inside this box ☐Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	09/847,208	
	<b>Filing Date</b>	May 1, 2001	
	<b>First Named Inventor</b>	Andrew Saxon	
	<b>Group/Art Unit</b>	1644	
	<b>Examiner Name</b>	Phuong N. Huynh	
<b>Total Number of Pages in This Submission</b>		<b>Attorney Docket Number</b>	39754-0672A

**ENCLOSURES (check all that apply)**

<input checked="" type="checkbox"/> <b>Fee Transmittal Form</b> <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> Exhibits <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> <b>Information Disclosure Statement with PTO-1449</b> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers <i>(for an Application)</i> <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Status Claimed <input type="checkbox"/> Statement under 3.73(b)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> <b>Additional Enclosure(s) (please identify below):</b> 106 References and Return Receipt Postcard
<b>Remarks</b>  <b>AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 (ATTORNEY DOCKET NO.: 39754-0672) FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER.</b>		


**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

<b>Firm or Individual name</b>	Leslie Mooi, Reg. No.: 37,047, HELLER EHRMAN LLP		
<b>Signature</b>			
<b>Date</b>	December 13, 2005	<b>Customer Number:</b>	25213

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
Express Mail Label: EV 765 988 707 US			
<b>Typed or printed name</b>	Jason A. Gonzalez		
<b>Signature</b>		<b>Date</b>	December 13, 2005

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2005

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**180.00**

## Complete if Known

Application Number	09/847,208
Filing Date	May 1, 2001
First Named Inventor	Andrew Saxon
Examiner Name	Phuong N. Huynh
Art Unit	1644
Attorney Docket No.	39754-0672A

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

08-1641 (39754-0672A)

HELLER EHRMAN LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	300	2001	150	Utility filing fee	
1002	200	2002	100	Design filing fee	
1003	200	2003	100	Plant filing fee	
1004	300	2004	150	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	
SUBTOTAL (1)					0

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below	Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>
Independent Claims	<input type="text"/>	-3** =	<input type="text"/>	X	<input type="text"/>
Multiple Dependent				<input type="text"/>	<input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	** Reissue independent claims over original patent
1205	50	2205	25	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**0**

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**180**


## SUBMITTED BY


Name (Print/Type)	Leslie Mooi	Registration No. (Attorney/Agent)	37,047	Telephone	650.324.6786
Signature	<i>Leslie Mooi</i>	Date	Dec 13, 2005		

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.			
Express Mail Label: EV 765 988 707 US			
Typed or print name	Jason A. Gonzalez		
Signature		Date	December 13, 2005



PATENT

Attorney Docket No.: 39754-0672A

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

Inventor(s): Andrew Saxon, et al.

Application No.: 09/847,208

Filed: May 1, 2001

Title: Fusion Molecules and Treatment of IgE-Mediated  
Allergic Diseases

Art Unit: 1644

Examiner: Phuong N. Huynh

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. §1.97**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

12/15/2005 GWORDOF1 00000044 081641 09847208

01 FC:1806 180.00 DA

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39754-0672A).

Respectfully submitted,

HELLER EHRMAN LLP

Dated: December 13, 2005

By: Leslie Mooi  
Leslie Mooi  
Reg. No.: 37,047

HELLER EHRMAN LLP  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: 1.650.324.7000  
Facsimile: 1.650.324.0638  
Customer No.: 25213

<b>INFORMATION DISCLOSURE STATEMENT</b> PTO-1449 DEC 13 2005 PATENT & TRADEMARK OFFICE		ATTY. DOCKET NO. 39754-0672A		SERIAL NO. 09/847,208			
		APPLICANT: Andrew Saxon, et al.					
		FILING DATE: 05/01/2001		GROUP: 1644			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,141,648	08/25/1992	Hylarides, et al.	210	635		
	5,358,710	10/25/1994	Sehon, et al.	424	178.1		
	5,512,283	04/30/1996	Byers, et al.	424	171.1		
	5,558,869	09/24/1996	Burks, Jr., et al.	424	276.1		
	5,560,915	10/01/1996	Patterson, et al.	424	275.1		
	5,637,454	06/10/1997	John B. Harley	435	005		
	5,645,820	07/08/1997	David Allen Halfer, et al.	424	041		
	5,672,683	09/30/1997	Friden, et al.	530	350		
	5,736,507	05/07/1998	Anna Maria Boots, et al.	514	002		
	5,843,449	12/01/1998	Anna Maria Boots, et al.	424	185.1		
	5,869,093	02/09/1999	Howard L. Weiner, et al.	424	451		
	5,880,103	03/09/1999	Urban, et al.	514	44		
	5,977,307	11/05/1999	Friden, et al.	530	350		
	6,103,697	08/15/2000	Bergstrand, et al.	514	14		
	6,214,974	04/10/2001	Rosenblum, et al.	530	391.9		
	6,228,373	05/08/2001	Bergstrand, et al.	424	278.1		
	6,228,374	05/08/2001	Bergstrand, et al.	424	278.1		
	6,287,792	09/11/2001	Pardridge, et al.	435	7.5		
	6,372,250	04/16/2002	Pardridge, et al.	424	450		
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 2000/005254	3 February 2000	WIPO	C07K	14/47	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 1999/067293	29 December 1999	WIPO		16/46	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Alvarez-Fernandez, Marcia, et al., "Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site", The Journal of Biological Chemistry, Vol. 274, No. 27, Issue of July 2, pp. 19195-19203, 1999							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	American Autoimmune Related Diseases Association, Questions and Answers, pp. 1-4, 07/26/2001 ( <a href="http://www.aarda.org/questions_and_answers.html">http://www.aarda.org/questions_and_answers.html</a> )	
	Resources for Health Professionals: Anaphylaxis, pp. 1-10, 09/18/2001 ( <a href="http://www.worldallergy.org/professional/allergy_update/anap.../anaphylaxisynopsis.shtm">http://www.worldallergy.org/professional/allergy_update/anap.../anaphylaxisynopsis.shtm</a> )	
	ANSARI, AA, et al., "Epitope Mapping of the Branched Chain Alpha-Ketoacid Dehydrogenase Dihydrolipoyl Transacylase (BCKD-E2) Protein that Reacts with Sera from Patients with Idiopathic Dilated Cardiomyopathy", (abstract), J Immunol, 153(10):4754-65, 15 November 1994	
	AroTec Diagnostics Limited - $\beta$ 2-Glycoprotein 1 (human), pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5002.htm">http://webnz.com/arotec/masa5002.htm</a> )	
	AroTec Diagnostics Limited - Myeloperoxidase (pANCA) Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5009.htm">http://webnz.com/arotec/masa5009.htm</a> )	
	AroTec Diagnostics Limited - Proteinase 3 (cANCA) Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5008.htm">http://webnz.com/arotec/masa5008.htm</a> )	
	AroTec Diagnostics Limited - La (SSB) Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5010.htm">http://webnz.com/arotec/masa5010.htm</a> )	
	AroTec Diagnostics Limited - Ro (SSA) Antigen, pp. 1-3, July 11, 2001 ( <a href="http://webnz.com/arotec/masa5011.htm">http://webnz.com/arotec/masa5011.htm</a> )	
	AroTec Diagnostics Limited - Sm Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5007.htm">http://webnz.com/arotec/masa5007.htm</a> )	
	AroTec Diagnostics Limited - RNP/Sm Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5006.htm">http://webnz.com/arotec/masa5006.htm</a> )	
	AroTec Diagnostics Limited - Scl-70 Antigen, pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5001.htm">http://webnz.com/arotec/masa5001.htm</a> )	
	AroTec Diagnostics Limited - Parietal Cell Antigen (H/K-ATPase), pp. 1-3, July 12, 2001 ( <a href="http://webnz.com/arotec/masa5004.htm">http://webnz.com/arotec/masa5004.htm</a> )	
	AroTec Diagnostics Limited - Jo-1 Antigen, pp. 1-2, 07/11/2001 ( <a href="http://webnz.com/arotec/masa5005.htm">http://webnz.com/arotec/masa5005.htm</a> )	
	"Autoantigen Sequences", pp. 1-3, 07/11/2001 ( <a href="http://129.206.51.31/mb/ana_base.html">http://129.206.51.31/mb/ana_base.html</a> )	
	"Autoimmune Disease: Rapid Progress in our Understanding of Immune Function Promises More Effective Treatments for Autoimmune Disorders", Nature Biotechnology, Vol. 18, pp. IT7-IT9, Supplement 2000	
	BARKER RN, et al., "Red Blood Cell Glycophorins as B and T-cell Antigens in Canine Autoimmune Haemolytic Anaemia", (abstract) Vet Immunol Immunopathol, 47(3-4):225-38, August 1995	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	"alphaB-Crystallin In Multiple Sclerosis", J. Immunol, Vol. 129-135, pp. 1-5, July 20, 2001 ( <a href="http://www.albany.net/~tjc/crystalline.html">http://www.albany.net/~tjc/crystalline.html</a> )	
	BAJRAMOVIC, JJ, et al., "Presentation of $\alpha$ B-Crystallin to T Cells in Active Multiple Sclerosis Lesions: An Early Event Following Inflammatory Demyelination", The American Association of Immunologists, Vol 164, pp. 4359-4366, 2000	
	BIGAZZI, PE, MD, Lecture on "Autoimmune Disease", The University of Connecticut, pp. 1-6, July 30, 2001, ( <a href="http://155.37.1.60/Lectures/PB/Autoimmune.html">http://155.37.1.60/Lectures/PB/Autoimmune.html</a> )	
	BONFA, E., et al., "Frequency and Epitope Recognition of Anti-Ribosome P Antibodies from Humans with Systemic Lupus Erythematosus and MRL/lpr Mice are Similar", (abstract), J Immunol; 140(1):3434-3437, 15 May 1998	
	BRIDGES, SL, Jr., et al., "T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis", Emerging Therapies for Rheumatoid Arthritis, Vol. 24, pp. 641-650, 1998	
	CAMBIER, JC, "Commentary: Inhibitory receptors abound?", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 5993-5995, 1997	
	CHAPMAN, MARTIN D., et al., "Recombinant Allergens for Diagnosis and Therapy of Allergic Disease", J Allergy Clin Immunol, pp. 409-418, 2000	
	CRITCHFIELD, JM, et al., "T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis", Science Feb 25; 263(5150):1139-43, 1994 (abstract)	
	DE PALMA, R, et al., "Use Of Altered Peptide Ligands To Modulate Immune Responses As A Possible Immunotherapy For Allergies", Allergy: 55: Suppl 61: 56-59, 2000	
	DECKER, PATRICE, et al., "Inhibition Of Caspase-3-Mediated Poly (ADP-Ribose) Polymerase (PARP) Apoptotic Cleavage By Human PARP Autoantibodies And Effect On Cells Undergoing Apoptosis", The Journal Of Biological Chemistry, © 2000 by The American Society For Biochemistry And Molecular Biology, Inc., Vol. 275, No. 12, pp. 9043-9046, 24 March 2000	
	DIETERICH, W., et al., Identification Of Tissue Transglutaminase As The Autoantigen Of Celiac Disease", Nat Med; 3(7):797-801, July 1997 (abstract)	
	Merck Corp., "Disorders With Type III Hypersensitivity Reactions", The Merck Manual, Sec. 12, Ch. 148, Hypersensitivity Disorders, July 12, 2001	
	DITZEL, HENRIK J., "Human Antibodies In Cancer And Autoimmune Disease", Immunologic Research; 21(2-3):185-193, 2000	
	EARNSHAW WC, et al., "Identification Of A Family Of Human Centromere Proteins Using Autoimmune Sera From Patients With Scleroderma", (abstract) Chromosoma, 91(3-4):313-321, 1985	
	ELKON, KB, et al., "Lupus Autoantibodies Target Ribosomal P Proteins", (abstract) J Exp Med, 162(2): 459-471, August 1 1985	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	FABIEN N., et al., "Autoantibodies Directed Against The Ribosomal P Proteins Are Not Only Directed Against A Common Epitope Of The P0, P1 And P2 Proteins", (abstract) J Autoimmune, 13(1): 103-110, August 1999	
	FARIA AM, et al., "Oral Tolerance: Mechanisms And Therapeutic Applications", (abstract), Adv Immunol, 73:153-264, 1999	
	FRAMPTON, G., et al., "Identification Of Candidate Endothelial Cell Autoantigens In Systemic Lupus Erythematosus Using A Molecular Cloning Strategy: A Role For Ribosomal P Protein P0 As An Endothelial Cell Autoantigen", Rheumatology (Oxford), (abstract) 39(10):1114-1120, October 2000	
	GIOVANNONI, G, et al., "Multiple Sclerosis And Its Treatment", (abstract) J R Coll Physicians Lond, 33(4):315-22, Jul-Aug 1999	
	GOLD, DANIEL P., et al., "T-Cell Receptor Peptides As Immunotherapy For Autoimmune Disease", Critical Reviews™ In Immunology, (abstract) 17:507-510, 1997	
	GOLD, DP, "Results Of A Phase I Clinical Trial Of A T-Cell Receptor Vaccine In Patients With Multiple Sclerosis. II. Comparative Analysis Of TCR Utilization In CSF T-Cell Populations Before And After Vaccination With A TCRV Beta 6 CDR2 Peptide", (abstract) J Neuroimmunol, 76(1-2):29-38, July 1997	
	GOLD, HA, et al., "The RNA Processing Enzyme RNase MRP Is Identical to the Th RNP And Related to RNase P", (abstract) Science, 245(4924):1377-80, 22 September 1989	
	GOTTLIEB, A.B., et al., Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study", (abstract) J Am Acad Dermatol, 43(4):595-604, October 2000	
	GUNNARSSON, ANDREAS, et al., "Molecular Properties Of The Goodpasture Epitope", The Journal Of Biological Chemistry, Vol. 275, No. 40, pp. 30844-30848, 6 October 2000	
	HASELDEN, B.M., et al., "Peptide-Mediated Immune Responses in Specific Immunotherapy", Int Arch Allergy Immunol, 122(4):229-37, 2000	
	HELLMARK, T., et al., "Characterization of Anti-GBM Antibodies Involved in Goodpasture's Syndrome", (abstract) Kidney Int, 46(3):823-9, September 1994	
	HIRANO, T., et al., "Human Tissue Distribution of TA02, which is Homologous with a New Type of Aspartic Proteinase, Napsin A", (abstract) Jpn J Cancer Res, 91(10):1015-21, October 2000	
	"Histones and Subclasses", July 30, 2001, Purified Antigens for Autoimmune Testing, ( <a href="http://www.immunovision.com/pg0019.htm">http://www.immunovision.com/pg0019.htm</a> )	
	HUGHES, G.R., The Antiphospholipid Syndrome: Ten Years On", (abstract) Lancet, 342(8867):341-344, August 7, 1993	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	KARLSSON, F.A., et al., "Major Parietal Cell Antigen in Autoimmune Gastritis with Pernicious Anemia is the acid-producing H <sup>+</sup> , K <sup>+</sup> adenosine Triphosphatase of the Stomach", (Abstract) J Clin Invest, 81(2):475-9, February 1988	
	KOZLOWSKI, MAYA, et al., "SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain", Molecular and Cellular Biology, pp. 2089-2099, Vol. 18, No. 4, April 1998	
	Kronus, "Addison's Disease", Enzyme Steroid 21-Hydroxylase (21-OH) Antibody, ( <a href="http://www.kronus.com/products/addisons.html">http://www.kronus.com/products/addisons.html</a> ), July 30, 2001	
	Kronus, "Celiac Disease", Tissue Transglutaminase (tTg) Autoantibody, ( <a href="http://www.kronus.com/products/celiac.html">http://www.kronus.com/products/celiac.html</a> ), July 30, 2001	
	Kronus, "Diabetes", ( <a href="http://www.kronus.com/products/diabetes.html">http://www.kronus.com/products/diabetes.html</a> ), July 30, 2001	
	Kronus, "Neuromuscular", Myasthenia Gravis, ( <a href="http://www.kronus.com/products/neuromuscular.html">http://www.kronus.com/products/neuromuscular.html</a> ), July 30, 2001	
	Kronus, "Thyroid Autoimmune", ( <a href="http://www.kronus.com/products/thyroid-auto.html">http://www.kronus.com/products/thyroid-auto.html</a> ), July 30, 2001	
	KROGSGAARD, M., et al., "Visualization of Myelin Basic Protein (MBP) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (HLA)-DR2-MBP 85-99 complex", (abstract), J Exp Med, April 17;191(8):1395-412, 2000	
	LARCHE, MARK, "Specific Immunotherapy", British Medical Bulletin, 56 (No. 4): 1019-1036, 2000	
	MALBEC, ODILE, et al., "The SH2 Domain-containing Inositol 5-Phosphatase SHIP1 Mediates Cell Cycle Arrest by FcγRIIB", JBC Papers in Press., pp. 1-29, May 18, 2001	
	MCNEIL, H. PATRICK, et al., "Anti-Phospholipid Antibodies are Directed Against a Complex Antigen that Includes a Lipid-Binding Inhibitor of Coagulation: β <sub>2</sub> -Glycoprotein I (apolipoprotein H)", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 4120-4124, Medical Sciences, June 1990	
	MIMORI, T., et al., "Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from Patients with Rheumatic Disorders", (abstract) J. Biol. Chem., 261(5):2274-8, February 15, 1986	
	MISAKI, Y., et al., "The 56K Autoantigen is Identical to Human Annexin XI", (Abstract) J. Biol. Chem., 269(6):4240-6, 11 February 1994	
	Immunovision (Brochure), "Mitochondrial Antigen", Purified Antigens for Autoimmune Testing, ( <a href="http://www.immunovision.com/pg0020.htm">http://www.immunovision.com/pg0020.htm</a> ), July 30, 2001	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	MU, F.T., et al., "EEA1, an Early Endosome-Associated Protein. EEA1 is a Conserved Alpha-Helical Peripheral Membrane Protein Flanked by Cysteine "Fingers" and Contains a Calmodulin-Binding IQ Motif", J. Biol. Chem., 270(22):13503-11, June 2 1995	
	Immunovision (Brochure), "nRNP", Purified Antigens for Autoimmune Testing, ( <a href="http://www.immunovision.com/pg0020.htm">http://www.immunovision.com/pg0020.htm</a> )	
	NAKAJIMA, ATSUGO, et al., "Antigen-Specific T Cell-Mediated Gene Therapy in Collagen-Induced Arthritis", The Journal of Clinical Investigation, Vol. 107, No. 10, pp. 1293-1301 May 2001	
	NEWKIRK, MARIANNA M., et al., "Autoimmune Response to U1 Small Nuclear Ribonucleoprotein (U1 snRNP) Associated with Cytomegalovirus Infection", Arthritis Res, 3: 253-258, July 30 2001	
	NORMAN, PHILIP S., "Therapeutic Potential of Peptides in Allergic Disease", Annals of Allergy, Vol. 71, pp. 330-333, September 1993	
	OKANO, Y., et al., "Autoantibody to Th Ribonucleoprotein (Nucleolar 7-2 RNA Protein Particle) in Patients with Systemic Sclerosis", Arthritis Rheum, 33(12):1822-8, December 1990, (abstract)	
	ONO, S.J., "Molecular Genetics of Allergic Diseases", Annu Rev Immunol, 18:347-66, 2000, (abstract)	
	ROCK, KENNETH L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides", Annu. Rev. Immunol., 17:739-79, 1999, (abstract)	
	CASCIO P, et al., "26Sproteasomes and Immunoproteasomes Produce Mainly N-Extended Cersions of an Antigenic Peptide", EMBO J, 20(10):2357-2366, May 15, 2001, (abstract)	
	SERWOLD T, et al., "ER Aminopeptidases Generate a Unique Pool of Peptides for MHC Class I Molecules", Nat. Immunol., July 2001, (abstract)	
	YEWDELL, JW., et al., "Not Such a Dismal Science: The Economics of Protein Sythesis, Folding, Degradation and Antigen Processing", Trends Cell Biol, 11(7):294-297, July 2001, (abstract)	
	FIEBINGER E., et al., "Cytokines Regulate Proteolysis in Major Histocompatibility complex Class II-Dependent Antigen Presentationby Dendritic Cells" J. Exp. Med., 193(8):881-892, April 16, 2001, (abstract)	
	STOLTZE L, et al., "Two New Proteases in the MHC Class I Processing Pathway", Nat. Immunol., 1(5):413-418, November 2000, (abstract)	
	MUNO D., et al., "Generation of both MHC Class I- and Class II-Restricted Antigenic Peptides from Exogenously Added Ovalbumin in Murin Phagosomes", FEBS Lett, 478(1-2)178-182, July 28, 2000, (abstract)	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	MANOURY B., et al., "An Asparaginyl Endopeptidase Processes a Microbial Antigen for Class II MHC Presentation", Nature, 396(6712):625-627, December 17, 1998, (abstract)	
	Auto Immune, Inc., "Overview of Oral tolerance Therapy" Research and Development – OT Technology, July 30, 2001, ( <a href="http://www.autoimmuneinc.com/R_D/tech.html">http://www.autoimmuneinc.com/R_D/tech.html</a> )	
	Immunovision (Brochure), "PCNA Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, ( <a href="http://www.immunovision.com/pg0061.htm">http://www.immunovision.com/pg0061.htm</a> )	
	PISETSKY, D.S., "The Role of Bacterial DNA in Autoantibody Induction", (abstract) Curr Top Microbiol Immunol, 247:143-155, 2000	
	RICKERT, M., et al., "Fusion Proteins for Combined Analysis of Autoantibodies to the 65-kda Isoform of Glutamic Acid Decarboxylase and Islet Antigen-2 in Insulin-Dependent Diabetes Mellitus", Clin Chem, 47(5):926-34, May 2001, (abstract)	
	Immunovision (Brochure), "Ribosomal P Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, ( <a href="http://www.immunovision.com/pg0021.htm">http://www.immunovision.com/pg0021.htm</a> )	
	RIDER, LISA G., et al., "Laboratory Evaluation of the Inflammatory Myopathies", Clinical and Diagnostic Laboratory Immunology, Vol. 2, No. 1, p. 1-9, Jan. 1995	
	RIESE, RICHARD J., et al., "Cathepsin S Activity Regulates Antigen Presentation And Immunity", J. Clin. Invest., Vol. 101, No. 11, 2351-2363, June 1998	
	Immunovision (Brochure), "Ro/SS-A Antigen", July 30, 2001, ( <a href="http://www.immunovision.com/pg0013.htm">http://www.immunovision.com/pg0013.htm</a> )	
	NOEL ROSE, et al., The Autoimmune Diseases: Table of Contents, Third Edition, Academic Press 1998	
	SARIC, TOMO, et al., "MHC Class I-Presented Antigenic Peptides are Degraded in Cytosolic Extracts Primarily by Thimet Oligopeptidase", JBC Papers in Press., Published July 30, 2001	
	Immunovision (Brochure), "Scl-70 Antigen", Purified Antigens for Autoimmune Testing" ( <a href="http://www.immunovision.com/pg0017.htm">http://www.immunovision.com/pg0017.htm</a> ), July 30, 2001	
	Immunovision (Brochure), "SMITH (sm) Antigen", Purified Antigens for Autoimmune Testing" ( <a href="http://www.immunovision.com/pg0015.htm">http://www.immunovision.com/pg0015.htm</a> ), July 30, 2001	
	SELA, M., "Specific Vaccines Against Autoimmune Diseases", C R Acad Sci III; 322(11):933-8, November 1999, (abstract)	
	SCHUPPAN, D, et al., "Identification of the Autoantigen of Celiac Disease", Ann N Y Acad Sci., 859:121-6, 17 November 1998, (abstract)	
	STEINMAN, L., "Multiple Sclerosis: a Coordinated Immunological Attack Against Myelin in the Central Nervous System", Cell, 85(3):299-302, May 3 1996, (abstract)	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	STEINMAN, L., et al., "Prospects for Specific Immunotherapy in Myasthenia Gravis" FASEB J.; 4(10):2726-31, July 1990, (abstract)	
	STENMARK, HARALD, et al., "Endosomal Localization of the Autoantigen EEA1 is Mediated by a Zinc-Binding FYVE Finger", The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 24048-24054, September 27 1996	
	Tan EM, "Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology", (abstract), Adv Immunol 1989, 44:93-151	
	TARGOFF IN, "Autoantibodies to Aminoacyl-Transfer RNA Synthetases for Isoleucine and Glycine. Two Additional Synthetases are Antigenic in Myositis; J Immunol, 144(5):1737-1743, 1 March 1990, (abstract)	
	National Institute of Allergy and Infectious Diseases, "Understanding Autoimmune Disease - What are some Examples of Autoimmune Diseases: Rheumatoid Arthritis. ( <a href="http://www.niaid.nih.gov/publications/autoimmune/examples.htm">http://www.niaid.nih.gov/publications/autoimmune/examples.htm</a> ), July 11, 2001	
	VAN SECHEL, ARIANNE C., et al., "EBV-Induced Expression and HLA-DR-Restricted Presentation by Human B Cells of aB-Crystallin, a Candidate Autoantigen in Multiple Sclerosis", The American Association of Immunologists, 1999	
	VAN VENROOIJ, W.J., et al., "Manual of Biological Markers of Disease", Table of Contents, Kluwer Academic Publishers,	
	VAN VENROOIJ, W.J., Venroij Research Team, Research Topics, General Introduction, "Autoantigens", (abstract), Department of Biochemistry, University of Nijmegen, 11 July 2001	
	WALLNER, BARBARA P., Short Analytical Review, "Peptide Therapy for Treatment of Allergic Diseases, Clinical Immunology and Immunopathology, Vol. 80, No. 2, August, pp. 105-109, 1996	
	WARDROP, III, R.M., et al, "Oral Tolerance in the Treatment of Inflammatory Autoimmune Disease, Inflamm. res., 48, pp. 106-119, 1990	
	YAMAMOTO, A.M., et al., "Anti-Titin Antibodies in Myasthenia Gravis: Tight Association with Thymoma of Nonthymoma Patients", Archives of Neurology, Vol 58, No.6, June 2001	
	GERMAIN, R.N., "The T Cell Receptor for Antigen: Signaling and Ligand Discrimination", The Journal of Biological Chemistry, Vol. 276, No. 38, pp. 35223-35226, July 2, 2001	
	Immunovision (Brochure), "La/SS-B", Purified Antigens for Autoimmune Testing, ( <a href="http://www.immunovision.com/pg0014.htm">http://www.immunovision.com/pg0014.htm</a> ), July 30, 2001	
	ROSE, N.R., "The Autoimmune Diseases: A Discussion of the Causes and Treatment of Autoimmune Diseases", American Autoimmune Related Diseases Associate, July 26, 2001	
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.